Research

Medical Sciences

Title :

Validation and Translation of the Vaccines as well as Dignostic Technologies Developed on Phase of ADMaC

Area of Research :

Medical Sciences

Focus Area :

Vaccines, Diagnostic Technologies

Principal Investigator :

Dr. Suresh KP, ICAR-National Institute of Veterinary Epidermiology and Disease Informatics (NIVEDI), Karnataka; Dr. Nagendra Nath Barman, College of Veterinary Sciences, AAU, Khanapara, Guwahati, Assam; Dr. Durlav Bora, Assam Agricultural University, Jorhat, Assam; Dr. Pankaj Deka, College of Veterinary Sciences, AAU, Khanapara, Guwahati, Assam; Dr. Baldev Gulati, National Research Centre on Equines, Hisar, Haryana; Dr. Seema Pegu, National Research Centre on Pig, Guwahati, Assam; Dr. Man

Co-PI:

Dr. Narayanan G, National Institute of veterinary Epidemiology and Disease Informatics, Bengaluru, Karnataka; Dr. Lukumoni Buragohain, College of Veterinary Sciences, AAU, Khanapara, Guwahati, Assam; Dr. Abhijit Deka, College of Veterinary Sciences, Assam Agricultural University, Jorhat, Assam; Dr. Deep Saikia, College of Veterinary Sciences, AAU, Khanapara, Guwahati, Assam; Dr. Nagalingam M, National Institute of veterinary Epidemiology and Disease Informatics, Bengaluru; Dr. Ajay Yadav, National Research Centre on Pig, Guwahati, Assam; Dr. Ramya Rajendran, Tamil Nadu Veterinary and Animal Sciences University, Chennai; Dr. Divakar Hemadri, National Institute of veterinary Epidemiolo

Contact info :

Timeline Start Year :

2021

Timeline End Year :

2025

Total Budget (INR):

 4,72,.9,139

Details

Executive Summary :

Major leads of Core Lab I (AAU, Guwahati) under ADMaC phase I include development of vaccinesagainst some of the endemic diseases like classical swine fever and Duck Plague. Again, importantleads were obtained under diagnostics which include both molecular as well as serological assaysthat could be used for early diagnosis of prevalent diseases.

Equipments :

Achievements :

Cell culture adapted duck plague virus(DPV)vaccine candidate (DPV/As/Km/19)has been identified and its immunogenicity was evaluated by a control animal experiment in ducks. The vaccine produced promising antibody titre including neutralization titre upto day60 post immunization. Indirect ELISA for detection of specific antibodies against DPV,CSFV, PCV2, JEV, Brucella spp. And Coxiella burnetiid have been optimized by using recombinant protein or immunogenic peptides as coating antigen. A competitive ELISA having DIVA potential for multi species Brucellosis has been developed and validated. Three lateral flow assay(LFA)for detection of JEV, DPV and Brucella specific antibodies have also been optimized, and validation process with licencing formalities of LFA for Brucella antibody detection

Outcome/Output:

1

Organizations involved

Implementing Agency :

ICAR- National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI), Karnataka

Funding Agency :

Department of Science and Technology (DBT)

Source:

 E-promis and Information received by Investigator

Related Research

Molecular Characterization of SIRT2 Point Mutations in Familial Hypertrophic Cardiomyopathy
International Cooperation Division
Design and Development of a Smartphone-based Non-invasive and Affordable Diabetes and Hypertension Screening Tool using PPG signals
Biomining endophytic fungi for selective mitogen activated protein kinase phosphatase-1 (MKP-1) inhibitor(s): A targeted approach for cancer therapeutics
Development of Multimodal Framework for the Diagnosis of Non-Communicable Diseases (COPD) Using Artificial Intelligence